Core Points - Genmab A/S announced the retirement of Birgitte Stephensen, Executive Vice President and Chief Legal Officer, after 23 years with the company, effective July 1, 2025 [1][2] - Greg Mueller has been appointed as the new Executive Vice President, General Counsel, and Chief Legal Officer, effective July 1, 2025, and will report to the President and CEO, Dr. Jan van de Winkel [1][3] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform the lives of people with cancer and other serious diseases by 2030 [5] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [6]

Core Insights - Genmab A/S announced promising results from the Phase 1b/2 EPCORE NHL-2 trial, demonstrating the efficacy of epcoritamab in combination with R-ICE for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) [2][4][5] Trial Results - The overall response rate (ORR) was reported at 87 percent, with a complete response (CR) rate of 65 percent and a partial response (PR) rate of 23 percent [2][6] - At six months, 81 percent of responses were ongoing, 74 percent of patients were progression-free, and 100 percent of patients were alive [2][6] - Among patients who progressed within 12 months after first-line treatment, the ORR was 85 percent and the CR rate was 55 percent [4] - For patients who progressed after 12 months from first-line therapy, the ORR was 91 percent and the CR rate was 82 percent [4] Safety Profile - The safety profile indicated low-grade cytokine release syndrome (CRS) with no treatment discontinuations due to treatment-emergent adverse events (TEAEs) [3][5] - The most common TEAEs included neutropenia (74 percent), anemia (68 percent), and thrombocytopenia (68 percent) [3] - Serious infections were reported in 16 percent of patients, with no Grade 5 TEAEs observed [3] Industry Context - DLBCL accounts for approximately 25-30 percent of all non-Hodgkin's lymphoma cases globally, with around 25,000 new cases diagnosed annually in the U.S. [6][7] - The investigational treatment with epcoritamab aims to address significant unmet needs in the management of R/R DLBCL and other hematologic malignancies [5][12] Future Development - Genmab is collaborating with AbbVie to further develop epcoritamab as a core therapy for B-cell lymphomas, with ongoing trials evaluating its use in various treatment lines [5][12] - The EPCORE NHL-2 trial is part of a broader clinical program aimed at advancing epcoritamab both as monotherapy and in combination therapies [8][12]

Core Viewpoint - Genmab's stock saw a nearly 4% increase following positive clinical trial results for its drug Rina-S, aimed at treating advanced uterine cancer, and an update on its share buyback program [1][2][5] Group 1: Clinical Trial Results - Genmab announced phase 1/2 clinical trial results for Rina-S, showing a confirmed objective response rate of 50% in patients with advanced uterine cancer who had prior treatments [2] - Study investigator Ira Winer highlighted the encouraging data from the trial, supporting further development of Rina-S as a potential therapy for advanced and recurrent endometrial cancer [4] Group 2: Share Buyback Program - Genmab updated investors on its share buyback program, which allows for the repurchase of up to 2.2 million shares by July 10, 2023, with nearly 2.08 million shares already bought for over 2.7 billion Danish kronor (approximately $411 million) [5] Group 3: Future Outlook - The combination of positive clinical trial results and the aggressive share buyback indicates that Genmab is confident in its development pipeline and future prospects [6][7]

Core Insights - Genmab A/S announced promising results from the Phase 1/2 RAINFOL™-01 trial for rinatabart sesutecan (Rina-S), showing a 50.0% confirmed objective response rate (ORR) in advanced endometrial cancer patients [2][3][6] - The study involved 64 heavily pre-treated patients, with a median follow-up of 7.7 months, and demonstrated significant anti-tumor activity [3][4] - Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), with ongoing evaluations in various cancers [10][11] Company Overview - Genmab is focused on developing innovative antibody-based medicines to address unmet needs in cancer treatment, particularly for gynecologic cancers [5][12] - The company has a robust pipeline, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform cancer treatment by 2030 [12] Clinical Trial Details - The RAINFOL-01 trial is an open-label, multicenter study evaluating Rina-S in solid tumors, with specific cohorts for endometrial cancer [6][7] - The B2 cohort results indicate that Rina-S 100 mg/m led to a 50.0% ORR, while the 120 mg/m cohort showed a 47.1% ORR, with no median duration of response reached [3][4][6] Treatment Context - Advanced endometrial cancer has limited treatment options after progression on standard therapies, highlighting the need for new therapies like Rina-S [8][9] - The incidence and mortality rates of endometrial cancer are increasing, emphasizing the urgency for effective management strategies [8] Safety Profile - Common treatment emergent adverse events included diarrhea, dyspnea, and urinary tract infections, with serious adverse events occurring in 31.8% and 50.0% of patients in the 100 mg/m and 120 mg/m cohorts, respectively [4][5] - No significant ocular toxicities or interstitial lung disease were observed, which are often concerns with antibody-drug conjugates [4]

Company Overview - Genmab A/S is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Product Pipeline and Vision - Genmab has developed a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies [2] - The company's vision by 2030 is to transform the lives of patients with cancer and other serious diseases through its "knock-your-socks-off" (KYSO) antibody medicines [2] Upcoming Events - Genmab's Chief Financial Officer, Anthony Pagano, will participate in a fireside chat at the 46th Goldman Sachs Annual Global Healthcare Conference on June 9, 2025 [1]

Core Insights - Genmab A/S will present new research from its late-stage portfolio at the 2025 ASCO Annual Meeting from May 30 to June 3 in Chicago, Illinois [1] - The presentations will include results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S) for recurrent/advanced endometrial cancer and long-term follow-up data from the EPCORE NHL-1 study of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma [2][8] Company Commitment - Genmab emphasizes its commitment to advancing antibody science for patients needing alternative treatment options, particularly for endometrial cancers with rising mortality rates [3] - The company is encouraged by Rina-S as a potential treatment option for endometrial cancer and continues to evaluate epcoritamab as a core therapy across B-cell malignancies in collaboration with AbbVie [3][15] Event Details - Genmab will host a virtual review of the Rina-S data presented at ASCO on June 2 at 4:00 PM CDT, with details available on their investor relations website [4] Abstracts and Presentations - Abstracts accepted for presentation at ASCO include key studies on Rina-S and epcoritamab, with specific presentation times outlined [5][7]

Company Overview - Genmab A/S is an international biotechnology company focused on improving the lives of patients through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Product Pipeline and Vision - Genmab has developed a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies [2] - The company's vision by 2030 is to transform the lives of people with cancer and other serious diseases through groundbreaking antibody medicines, referred to as "knock-your-socks-off" (KYSO) therapies [2] Upcoming Events - Judith Klimovsky, Chief Development Officer of Genmab, will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference on June 5, 2025, at 9:20 EDT [1]

Core Insights - Genmab A/S is a biotech innovator focusing on antibody engineering and has a strategy that includes direct commercialization of its products Tivdak and Epcoritamab, as well as monetizing through partnerships and licensing drugs like Darzalex and Kesimpta [1] Group 1 - The company retains its value through innovative antibody engineering [1] - Genmab's strategy involves both direct product sales and partnerships for drug monetization [1]

Core Insights - Genmab is presenting 14 abstracts on epcoritamab at the 30th European Hematology Association Congress, showcasing its development across various patient populations and treatment settings [1][4] - Epcoritamab is a T-cell engaging bispecific antibody designed for treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [6][7] Development Program - The abstracts include data from Phase 1/2 trials evaluating epcoritamab in combination with other therapies for relapsed/refractory DLBCL and previously untreated DLBCL [2][4] - Key trials include EPCORE NHL-2 and NHL-5, focusing on combinations with rituximab and polatuzumab vedotin [2][5] Presentation Details - Oral presentations will occur on June 15, 2025, featuring significant findings from the EPCORE NHL-2 and NHL-5 trials [5] - Additional results from NHL-1 and NHL-3 trials will be presented as posters, highlighting three years of follow-up data [2][5] Regulatory Status - Epcoritamab has received regulatory approval in specific lymphoma indications in the U.S., Japan, and the EU, and is co-developed with AbbVie [7][10] - The companies are pursuing further international regulatory approvals for additional indications [7] Future Directions - Genmab and AbbVie are conducting five ongoing Phase 3 trials to evaluate epcoritamab's efficacy as a monotherapy and in combination therapies across various hematologic malignancies [8][9] - The companies aim to establish epcoritamab as a core therapy for B-cell malignancies [4][8]

Genmab Announces Financial Results for the First Quarter of 2025 May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights "Our commitment to advancing our late-stage programs was reflected in the progress we made in the first quarter of the year. Both EPKINLY and Tivdak expanded their reach with approvals in additional territories and the updated Rina-S data presented at SGO reinforces its potential as a treatment option for patients with advanced ovarian cancer, ...